

DAFTAR PUSTAKA

1. Kementrian Kesehatan RI. Situasi penyakit kanker Indonesia. Pus Data dan Inf Kemenkes RI. 2015;(2):31–3.
2. Smolarz B, Zadrożna Nowak A, Romanowicz H. Breast cancer—epidemiology, classification, pathogenesis and treatment. *Cancers (Basel)*. 2022;14(10):1–27.
3. World Health Organization (2021). Breast cancer. World Health Organization Western Pacific Region. Diakses Oktober 2022.
4. Andreas C, Carey LA. Latest world cancer statistics global cancer burden rises to 14 . 1 million new cases in 2012 : marked increase in breast cancers must be addressed. *Int Agency Res Cancer, World Heal Organ*. 2013;(December):2012–4.
5. Lim YX, Lim ZL, Ho PJ, Li J. Breast cancer in Asia: incidence, mortality, early detection, mammography programs, and risk-based screening initiatives. *Cancers (Basel)*. 2022;14(17):1–21.
6. Youn HJ, Han W. A review of the epidemiology of breast cancer in Asia: focus on risk factors. *Asian Pacific J Cancer Prev*. 2020;21(4):867–80.
7. Kementerian Pemberdayaan Perempuan dan Perlindungan Anak Republik Indonesia (2022). Kementerian pemberdayaan perempuan dan perlindungan anak Republik Indonesia dorong masyarakat lakukan deteksi dini kanker payudara dengan SADARI dan SADANIS. Diakses November 2022.
8. Wiguna N, Manuaba I. Karakteristik pemeriksaan imunohistokimia pada pasien kanker payudara di rsup sanglah periode 2003-2012. (2014)*E-Jurnal Med Udayana /*. 2012;147:1–13.
9. Azzahra D. Skripsi respon kemoterapi pada pasien kanker payudara tipe triple-negative (tnbc) di rsup haji adam malik periode 2011 – 2015. Medan: Fakultas Kedokteran, Universitas Sumatera Utara;2017;(1):1-33.
10. Urru SAM, Gallus S, Bosetti C, Moi T, Medda R, Sollai E, et al. Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients. *BMC Cancer*. 2018;18(1):1–11.
11. Syaifudin A. Korelasi antara ekspresi Cd44 terhadap grading histopatologi,

- metastasis, disease free survival, dan overall survival pada wanita penderita kanker payudara. *Compos Part A Appl Sci Manuf.* 2020;1(1):1–60.
12. Lim DW, Yin L, Mulcahy JR, Hermann N, (Elise) Min H, Boileau JF, et al. Breast cancer. *Surg Oncol Man.* 2020;49–100.
 13. American Cancer Society. Cancer facts and figures 2017. *Genes Dev.* 2017;21(20):2525–38.
 14. Ullah MF. Breast cancer: metastasis and drug resistance. volume 115. *Advances in Experimental Medicine and Biology*; 2019. p. 51–64.
 15. Lei S, Zheng R, Zhang S, Wang S, Chen R, Sun K, et al. Global patterns of breast cancer incidence and mortality: a population-based cancer registry data analysis from 2000 to 2020. *Cancer Commun.* 2021;41(11):1183–94.
 16. Jacobs L, Bevers TB, Helvie M, Lehman CD, Bonaccio E, Monsees B, et al. Breast cancer screening and diagnosis, version 3.2018. *JNCCN J Natl Compr Cancer Netw.* 2018;16(11):1362–89.
 17. Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2019;30(8):1194–220.
 18. Townsend DW, Beyer T, Blodgett TM. PET/CT scanners: a hardware approach to image fusion. *Semin Nucl Med.* 2003;33(3):193–204.
 19. Khattak MS, Ahmad F. Role of fine needle aspiration cytology in diagnosis of palpable breast lesions and their comparison with histopathology. *J Ayub Med Coll Abbottabad.* 2020;32(1):83–6.
 20. Keputusan Menteri Kesehatan RI. Pedoman nasional pelayanan kedokteran tatalaksana kanker payudara. Peraturan Menteri Kesehatan RI. 2018:4-111.
 21. Manjunath M, Choudhary B. Triple-negative breast cancer: a run-through of features, classification and current therapies. *Oncol Lett.* 2021;22(1):1–21.
 22. Fisusi FA, Akala EO. Drug combinations in breast cancer therapy. *Pharm Nanotechnol.* 2019;7(1):3–23.
 23. Reddy KB. Triple-negative breast cancers: an updated review on treatment options. *Curr Oncol.* 2011;18(4):173–9.
 24. von Minckwitz G, Martin M. Neoadjuvant treatments for triple-negative breast cancer (TNBC). *Ann Oncol.* 2012;23(SUPPL. 6):vi35–9.

25. Adiputra PAT, Sudarsa IW. Skoring prognostik survival pasien *triple negative* breast cancer berbasis immunoscore. JBN (Jurnal Bedah Nasional). 2021;5(2):65.
26. Vagia E, Mahalingam D, Cristofanilli M. The landscape of targeted therapies in TNBC. *Cancers (Basel)*. 2020;12(4).
27. Haakensen VD, Lingjærde O, Lüders T, Riis M, Prat A, Troester MA, et al. Gene expression profiles of breast biopsies from healthy women identify a group with claudin-low features. *BMC Med Genomics*. 2011;4(1):77.
28. Ismail-Khan R, Bui MM. A review of triple-negative breast cancer. *Cancer Control*. 2010;17(3):173–6.
29. Cahyawati PN. Imunoterapi pada Kanker Payudara. WICAKSANA, J Lingkungan Pembang. 2018;2(1):52–5.
30. Singh DD, Yadav DK. TNBC: Potential targeting of multiple receptors for a therapeutic breakthrough, nanomedicine and immunotherapy. *Biomedicines*. 2021;9(8):1–26.
31. Anders C, Carey LA. Understanding and treating *triple negative* breast cancer. NIH Public Access. 2010;22(11):1233–43.
32. Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JAW, et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system. *J Clin Oncol*. 2007;25(15):2127–32.
33. Sopiudin DM. Besar sampel dan cara pengambilan sampel dalam penelitian kedokteran dan kesehatan. Jakarta: Salemba Medika; 2010.
34. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. *J Clin Oncol*. 2008;26(8):1275–81.
35. Farisyi MA, Khambri D. Analisis survival pasien kanker payudara usia muda di RSUP DR . M . Djamil Padang Tahun 2008-2017 Artikel Penelitian. 2018;7(Supplement 4):25–9.
36. Lydiatt WM, Patel SG, O’Sullivan B, Brandwein MS, Ridge JA, Migliacci JC, et al. Head and neck cancers-major changes in the american joint committee on cancer eighth edition cancer staging manual. *CA Cancer J*

- Clin. 2017;67(2):122–37.
37. Albergaria A, Ricardo S, Milanezi F, Carneiro V, Amendoeira I, Vieira D, et al. Nottingham prognostic index in triple-negative breast cancer: a reliable prognostic tool. *BMC Cancer*. 2011;11.
 38. Soediro R, Prajogi G Ben, Djakaria M. *Radioterapi*. Vol. 1. 2010.
 39. Eralp Y, Kılıç L, Alço G, Başaran G, Doğan M, Dinçol D, et al. The outcome of patients with *triple negative* breast cancer: the turkish oncology group experience. *Meme Sagligi Derg / J Breast Heal*. 2014;10(4):209–15.
 40. da Silva JL, de Paula BHR, Small IA, Thuler LCS, de Melo AC. Sociodemographic, clinical, and pathological factors influencing outcomes in locally advanced *triple negative* breast cancer: a brazilian cohort. *Breast Cancer Basic Clin Res*. 2020;14.
 41. Reddy SM, Barcnas CH, Sinha AK, Hsu L, Moulder SL, Tripathy D, et al. Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity. *Br J Cancer*. 2018;118(1):17–23.
 42. Baranova A, Krasnoselskyi M, Starikov V, Kartashov S, Zhulkevych I, Vlasenko V, et al. Triple-negative breast cancer: current treatment strategies and factors of negative prognosis. *J Med Life*. 2022;2022(2):153–61.
 43. Wang M, Hou L, Chen M, Zhou Y, Liang Y, Wang S, et al. Neoadjuvant chemotherapy creates surgery opportunities for inoperable locally advanced breast cancer. *Sci Rep*. 2017;7.
 44. Barcelo A, Duffett-Leger L, Pastor-Valero M, Pereira J, Colugnati FAB, Trapido E. The role of education on cancer amenable mortality among non-hispanic blacks & non-hispanic whites in the united states (1989–2018). *BMC Cancer*. 2021;21(1):1–13.
 45. Liu D, Ba Z, Ni X, Wang L, Yu D, Ma X. Apparent diffusion coefficient to subdivide breast imaging reporting and data system magnetic resonance imaging (BI-RADS-MRI) category 4 lesions. *Med Sci Monit*. 2018;24:2180–8.